25 May LNP technology in drug delivery – how lipid nanoparticles became the backbone of modern RNA therapeutics
For most of the history of RNA research, the molecule’s therapeutic promise was undermined by a fundamental problem: RNA is unstable, immunogenic, and unable to cross cell membranes on its own. You could design a sequence that encoded exactly the right protein, synthesise it cleanly — and watch it degrade before reaching its target. The biology was understood; the delivery was the bottleneck.
Lipid nanoparticles solved that problem. Not all at once, and not simply — but the arc of LNP development over six decades produced the delivery technology that made RNA therapeutics clinically viable. The mRNA vaccines of 2020–2021 were the most visible expression of that achievement. They were not, however, the end of the story. They were the proof of concept that opened the pipeline.
The Building Blocks: What Makes a Lipid Nanoparticle Work
A lipid nanoparticle is not a single material. It is a four-component system, and the behaviour of the whole depends on the properties of each part and how they interact.
The ionisable lipid is the functional core. At low pH — the conditions used during formulation — it carries a positive charge that facilitates electrostatic interaction with negatively charged nucleic acids, enabling efficient encapsulation. At physiological pH, it becomes neutral, which reduces toxicity and immune activation in circulation. When the LNP is taken up by a cell and enters the endosome — where pH drops again — the ionisable lipid destabilises the endosomal membrane, facilitating release of the payload into the cytoplasm. The design of the ionisable lipid is arguably the single most consequential variable in LNP performance.
The phospholipid contributes to membrane structure and fluidity, and influences how readily the LNP membrane fuses with the endosomal membrane after cellular uptake.
Cholesterol stabilises the lipid bilayer and affects rigidity, particle size, and in vivo behaviour. Its inclusion also improves cellular uptake by facilitating membrane fusion.
The PEG-lipid provides a hydrophilic coating on the particle surface, preventing aggregation, extending circulation half-life by reducing opsonisation, and modulating immune recognition. The PEG density and chain length affect both pharmacokinetics and how efficiently cells can internalise the particle — a balance that requires careful optimisation.
These four components, combined with the nucleic acid payload, are processed under controlled conditions to produce particles in the 60–200 nm range, with encapsulation efficiencies that determine how much of the active payload is actually protected and deliverable.
The Pivot Point: Why mRNA Needed LNPs and What That Unlocked
The 1978 demonstration that mRNA could be encapsulated in liposomes was conceptually important but practically limited by the materials available at the time. Early lipid formulations were poorly tolerated and inefficient at endosomal escape. Progress was incremental, but it was consistent.
The approval of patisiran (Onpattro) by the FDA in 2018 — the first siRNA therapeutic using LNP delivery — marked the clinical validation of the platform. It demonstrated that ionisable lipid-based LNPs could deliver nucleic acid payloads safely and efficaciously in humans, targeting hepatocytes through apolipoprotein E-mediated uptake.
The COVID-19 vaccines accelerated everything. The BNT162b2 and mRNA-1273 formulations used ionisable lipid LNPs developed through years of prior work on siRNA delivery. What they added was the demonstration that LNP-mRNA could be manufactured at scale, distributed globally, and tolerated by populations of hundreds of millions. The platform had been validated in clinical use before; now it had been validated at a scale that removed any remaining institutional scepticism about its viability.
According to the Nature Reviews Materials, lipid nanoparticle technology represents one of the most significant advances in drug delivery of the past two decades, enabling the clinical translation of RNA therapeutics across multiple disease areas.
Beyond Vaccines: The RNA Therapeutics Pipeline LNPs Now Enable
The significance of LNP technology is not confined to infectious disease vaccines. It extends across the growing RNA therapeutics pipeline — and that pipeline is considerably broader than is often appreciated outside specialist circles.
siRNA therapeutics targeting the liver are the most clinically advanced application beyond vaccines, with multiple approved products and a robust development pipeline. The hepatic tropism of standard LNP formulations — driven by ApoE adsorption and LDL receptor-mediated uptake — is a feature in this context, not a limitation.
Self-amplifying RNA (saRNA) platforms are attracting considerable interest because they can achieve therapeutic protein expression at substantially lower doses than conventional mRNA, with implications for both cost and tolerability. Formulating saRNA presents distinct challenges from mRNA, particularly around particle size and stability, which is driving active work on LNP composition optimisation for this payload class.
Gene editing applications — including CRISPR-Cas9 and base editing — require co-delivery of guide RNA and mRNA or protein components, placing complex demands on LNP design that standard four-component formulations do not always meet without modification.
Cancer immunotherapy applications, including personalised neoantigen vaccines and in situ tumour-targeting approaches, require LNPs that can reach targets beyond the liver — lymph nodes, tumour microenvironments, specific immune cell populations. This is where the field is working hardest on the next generation of the technology. For more on advances in cancer treatment research, see MedicalResearch.com’s cancer research coverage.
The Unresolved Challenges — Where the Science Is Still Being Worked Out
LNP technology is mature in certain applications and still developing in others. The challenges that remain are real, and acknowledging them is necessary for any honest assessment of the field.
Endosomal escape efficiency remains imperfect. The fraction of LNP payload that successfully escapes the endosome and reaches the cytoplasm — rather than being degraded in the lysosome — is typically estimated in the low single-digit percentages. Improving this efficiency is one of the most active areas of ionisable lipid design.
Extrahepatic targeting is the capability the field needs for most applications outside infectious disease vaccines and hepatic gene silencing. Engineering LNPs that selectively reach lung, muscle, central nervous system, or specific immune cell populations requires either chemical modification of the particle surface or exploitation of selective organ targeting (SORT) approaches — both of which are areas of active investigation.
Manufacturing scalability is a practical constraint that becomes a bottleneck earlier than many development programmes expect. The microfluidic or impingement jet mixing processes used for LNP production behave differently at scale, and process characterisation under QbD principles is a prerequisite for any cGMP manufacturing campaign.
Stability — both during storage and after reconstitution — remains an active formulation challenge, particularly for mRNA payloads that are inherently labile.
What LNP Development Actually Requires: The Formulation Expertise Gap
The critical implication of LNP complexity for any programme working with RNA payloads is that formulation is not a downstream problem. It is a programme-defining variable that should be considered at the point of target and payload selection, not after the biology has been characterised.
Getting LNP formulation right requires depth in lipid chemistry, particle characterisation, encapsulation process development, stability science, and cGMP manufacturing — simultaneously. For most pharmaceutical and biotech companies, that combination does not exist in-house at the scale needed for full development. It is precisely this gap that specialist CDMO partners are positioned to fill.
A biotech company with genuine end-to-end capability in LNP development — from RNA synthesis through formulation development to cGMP manufacturing — removes the coordination risk that comes from assembling those capabilities across multiple vendors. SyVento BioTech, based near Kraków, offers exactly that: a single-site, cGMP-compliant facility with a 100% PhD-qualified R&D team experienced in liposomal and LNP formulation development across payload classes including mRNA, siRNA, saRNA, DNA, and proteins.
The RNA therapeutics era is not a future state. It is happening now, across an expanding pipeline of indications and modalities. The companies that will shape it are those who get the delivery right.
Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on May 25, 2026 by Marie Benz MD FAAD